NEW YORK The value of the market for specialty injectable drugs will top $90 billion by 2014, according to a report by medical technology consulting firm Greystone Research Associates.
The firm based its estimate on an analysis of the eight largest specialty injectable therapeutic segments –– including autoimmune disease, metabolic disease, reproductive health, viral infections and others –– while also examining the relationship between product dosage forms, packaging and revenue growth. The data are included in the report, titled “Injectable Drug Delivery: Drugs, Devices, Targets, Markets and Forecasts.”
“The chronic nature of diseases and conditions in these segments makes repetitive dosing a fact of patient life,” Greystone's managing director George Perros said. “While efforts to develop drugs in sustained-release formulations for less-frequent dosing have yielded some success, the availability of therapies in safe and simple devices and packages remains an important element of patient acceptance.”